Miroprofen, an imidazopyridine derivative, possesses anti-inflammatory properties. It was shown that this compound could be effective in suppressing pain responses and acute inflammation accompanied by increased vascular permeability. Analgesic effect of this compound was studied in post-extraction pain. However, information about the current study of this agent is not available.

NLG919 is a novel small-molecule IDO-pathway inhibitor. NLG919 potently inhibits this pathway in vitro and in cell-based assays. It is orally bioavailable and has a favorable pharmacokinetic and toxicity profile. In mice, a single oral administration of NLG919 reduces the concentration of plasma and tissue Kyn by ∼ 50%. Using IDO-expressing human monocyte-derived DCs in allogeneic MLR reactions, NLG919 potently blocked IDO-induced T cell suppression and restored robust T cell responses with an ED50=80 nM. Similarly, using IDO-expressing mouse DCs from tumor-draining lymph nodes, NLG919 abrogated IDO-induced suppression of antigen-specific T cells (OT-I) in vitro. In vivo, in mice bearing large established B16F10 tumors, administration of NLG919 markedly enhanced the anti-tumor responses of naïve, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA

PG-545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in the extracellular matrix (ECM), thus limiting subsequent binding to receptors. Importantly, PG-545 also inhibits heparanase, the only endoglycosidase which cleaves HS chains in the ECM. The anti- respiratory syncytial virus (RSV) activity of PG-545 was due to both partial inhibition of the virus attachment to cells and a more profound interference with some post-attachment steps as PG-545 efficiently neutralized infectivity of the cell-adsorbed virus. The anti-RSV activity of PG-545 was reduced when tested in the presence of human nasal secretions. Serial passages of RSV in the presence of increasing concentrations of PG-545 selected for weakly resistant viral variants that comprised the F168S and the P180S amino acid substitutions in the viral G protein. PG-545 has an immunomodulatory properties. PG-545 stimulates innate immune responses against tumours in preclinical cancer models. PG-545 is in phase I clinical trial for the treatment of pancreatic cancer.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.

Olpimedone was developed as an anti-rheumatic agent and analgesic, however, the drug that has never been marketed. Information about the current use of olpimedone is not available.